Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling

Supplemental Data

• Supplementary Figure S-1 (.pdf, 1.1 MB) - S-1: M-mode echocardiographic analyses:
• Supplementary Figure S-2 (.pdf, 507 KB) - S-2: Graphical representations of relative band intensities of Western Blot analyses in different experimental groups.
• Supplementary Figure S-3 (.pdf, 362 KB) - S-3: Western blot analyses showing successful knockdown of target proteins by respective siRNA treatments in AngII treated cardiac fibroblasts in vitro
• Supplementary Figure S-4 (.pdf, 94 KB) - S-4: Root Mean Square Deviation (RMSD) across the simulation length for Rat_TAK1
• Supplementary Figure S-5 (.pdf, 583 KB) - S-5: Effect of PPAR?? domains upon modulation of PPARα::TAK1 interaction and TAK1-driven non-canonical TGF-β pathway in AngII treated cardiac fibroblasts.
• Supplemental table S1 (.docx, 16 KB) - Supplementary Table S1: Binding free energies of different agonists to PPARα obtained via Molecular docking (AutoDock Vina 1.1.2 extension of UCSF chimera) are tabulated in Column A. Experimentally derived or previously reported binding free energies are tabulated in Column B. For AA, binding free energy was calculated from Fluorescence and CD titrations. For Fenofibrate (42), Iloprost (40) and TIPP-703 (41) previously reported docking scores are tabulated (in Column B).
• Supplemental table S2 (.docx, 18 KB) - Supplementary Table S2A: Interacting residues between PPARα and TAK1 in the best fit molecular docking model which is selected on the basis of best fit HADOCK score . Supplementary Table S2B: Details for the best fit docked structure of PPARα -TAK1 interactome using HADDOCK.
• Supplemental table S3 (.docx, 17 KB) - Supplementary Table 3A-D: list of primers used.
• Supplemental table S4 (.docx, 23 KB) - Supplementary Table 4: list of antibodies used.